PolyNovo (PNV) Shares Go Global With European Update

The Polynovo Ltd (ASX: PNV) share price leaped 10% higher today after announcing its first product orders for the German, Austrian and Swiss markets. 

Who Is Polynovo Ltd?

PolyNovo is an Australian medical device company that designs, develops, and manufactures dermal regeneration solutions using its patented NovoSorb biodegradable polymer technology. 

Its current product is NovoSorb BTM (Biodegradable Temporising Matrix), a wound dressing intended for the treatment of full-thickness wounds and burns where the dermal structure requires a split-thickness skin graft for final closure.

Think of it like a ‘sheet’ that goes over affected areas and lets the skin tissue heal ‘through it’, lessening the risks of rejection and infection.

What Happened?

Pleasingly for investors, today Polynovo said they shipped first orders of NovoSorb BTM in preparation for surgeries, with the first surgery taking place on Sunday.

“The enthusiasm and engagement of surgeons for NovoSorb BTM is very exciting and likely to bring further product sales in the near term,” PolyNovo’s CEO, Paul Brennan said.

“We are off and running in Europe,” added Chairman David Williams. “When we announced our EU approval in mid-December we said we expected near term sales. We have achieved that now and better still we have the first patients being treated.”

Management’s seemingly very positive commentary follows a trading halt in PolyNovo’s shares earlier this month.

According to Yahoo!Finance, PolyNovo is a company valued by investors at over $1 billion however its sales were last reported at just $2 million per month.

I think you’ll admit, that’s quite a high valuation.

If you want to take your investing knowledge to the next level, try one of our free value investing courses today.

Whether you’re just starting on your journey, want confidence in what you’re already doing or hope to push your skills to the next level, we’ve got you covered. Click here to browse our free courses.

Free report: 3 cloud stocks to buy now

As we emerge from COVID-19, some tech companies are growing faster than ever. Rask’s investment analysts have identified 3 growth stocks set to benefit. Big time.

We’ll send you our report for free, including the names, ticker codes and analysis when you enter your email address below.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Free report: 3 cloud stocks to buy now

As we emerge from COVID-19, some tech companies are growing faster than ever. Rask’s investment analysts have identified 3 growth stocks set to benefit. Big time.

Click here to access this report for free, including the names, ticker codes and analysis.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Keep reading: